It is worth considering AbbVie (ABBV), which belongs to the Zacks Large Cap ... the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is ...

For many, dividend investing is all about the yield. They search for stocks that offer high yields, thinking that’s enough to ...

Piotr Swat / SOPA Images / LightRocket via Getty Images AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its purchase of Cerevel ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award a seed grant of $610,000 to Justus ...

$60,000 of ABBVIE INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "International tax issues and pharmaceutical ...

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

AbbVie (NYSE:ABBV) underwent analysis by 17 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a concise overview of recent ratings ...

Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

On Friday, Guggenheim Securities adjusted its financial outlook for shares of AbbVie Inc . (NYSE:ABBV), reducing the price target to $212 from the previous $221, while still recommending a Buy ...